“Should anti-CGRP monoclonal antibodies always be the drug of first choice for migraine prophylaxis in Brazil? - a pharmacoeconomic study”, Headache Med, vol. 15, no. 3, pp. 170–174, Sep. 2024, doi: 10.48208/HeadacheMed.2024.34.